On September 8, 2022 Caris Life Sciences(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, reported that the company and partners within its Precision Oncology Alliance (POA) will collectively present nine studies covering a diversity of tumor types and genomic alterations at the 2022 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress from September 9-13, 2022 (Booth #407) (Press release, Caris Life Sciences, SEP 8, 2022, View Source [SID1234619301]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The depth and range of research being presented by Caris and the POA demonstrates the value this collaboration brings to the broader oncology community," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. "The study findings provide critical insights into cancer biology and treatment outcomes that will help drive further clinical research and better inform diagnoses, clinical and therapeutic decision-making for oncology practices."

"Enabling clinicians to make the best treatment choices, researchers to discover novel cancer biology, and the biopharmaceutical industry to develop the next breakthrough medicines are foundational goals of Caris," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. "Data presented at this year’s ESMO (Free ESMO Whitepaper) Congress highlight the value of Caris’ comprehensive approach to molecular profiling built from our extensive data along with our AI-driven platform – which combines data from DNA (Whole Exome), RNA (Whole Transcriptome), and protein profiling with real-world clinical evidence from over 400,000 lifetime cases – to better understand the biological hallmarks of cancers and ultimately improve outcomes for all cancer patients."

The Caris Precision Oncology Alliance includes 70 cancer centers and academic institutions worldwide. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and advance research in cancer precision medicine. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, POA member institutions have access to Caris CODEai, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient.

Data to be presented by Caris and the POA include an oral presentation focusing on transcription factor expression in extra-pulmonary small cell carcinomas. Other notable topics explored in these abstracts include next generation sequencing of large real-world tumor databases, genomic and immune mapping of patients undergoing experimental therapies in clinical trials and investigations of changing tumor microenvironments for solid tumors:

Comparative Expression of Driver Transcription Factors in Extra-Pulmonary Small Cell Carcinoma (Abstract Number: 899MO)
September 12, 2022, 09:05-09:10 CEST
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET+ colorectal carcinoma as a unique molecular subset of CRC (Abstract Number: 72P)
September 10, 2022, 10:00-11:00 CEST
Pan-tumor survey of ROS1 fusions detected by next-generation RNA sequencing (Abstract Number: 105P)
September 10, 2022, 10:00-11:00 CEST
The Heterogeneic Molecular Landscape of Ovarian Cancer Metastases (OCM) (Abstract Number: 594P)
September 11, 2022, 13:00-14:00 CEST
The Molecular and Immune Landscape of Recurrent Head and Neck squamous cell Carcinoma (HNSCC) in Patients Undergoing Definitive Therapy (Abstract Number: 699P)
September 11, 2022, 14:00-15:00 CEST
CLEC3B mRNA expression levels are linked to distinct genetic backgrounds, transcriptomic signatures and survival in NSCLC (Abstract Number: 1723P)
September 11, 2022, 16:00-17:00 CEST
Tumor Microenvironment (TME) of HRAS Mutated Non-Small Cell Lung Cancer (NSCLC) (Abstract Number: 1066P)
September 12, 2022, 12:00-13:00 CEST
Comprehensive molecular profiling of squamous non-small cell lung cancer by smoking status (Abstract Number: 1052P)
September 12, 2022, 12:00-13:00 CEST
Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer (Abstract Number: 1771P)
September 12, 2022, 15:00-16:00 CEST
Poster and abstract summaries of this research will be available onsite at Caris’ booth #407. The full abstracts are available through the official ESMO (Free ESMO Whitepaper) website.

On September 8, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper), which will be held in person from 9-13 September 2022 in Paris, France (Press release, Kazia Therapeutics, SEP 8, 2022, View Source [SID1234619299]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will summarise key findings of the completed phase II study of paxalisib in glioblastoma, which was previously the subject of a poster presentation at the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, IL, in June 2022. The presentation will provide additional detail on pharmacokinetics and pharmacodynamics. The presentation will be delivered by Professor John de Groot, Division Chief of Neuro-Oncology at the University of California, San Francisco, one of the principal investigators on the study.

On September 8, 2022 EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, reported that its Chief Business Officer and Head of Finance, Dr. Gregory Wade, will provide a corporate presentation at 11:25 AM ET on Wednesday, September 14, 2022, as part of the annual Baird Global Healthcare Conference in New York (Press release, EXUMA Biotechnology, SEP 8, 2022, View Source [SID1234619298]). Dr. Wade will be available for one-on-one investor meetings during the conference. Please contact your Baird representative to schedule a meeting with Greg.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 8, 2022 Entrepreneurial Accelerator Program (EAP) portfolio company Oleolive, Inc. reported that it has been awarded a Small Business Technology Transfer (STTR) Phase 1 $400,000 research grant from the National Cancer Institute for "Chemosensitization of Glioblastoma by Propentofylline (Press release, Oleolive, SEP 8, 2022, View Source [SID1234619296])." Drs. Nhan Tran and Joseph Loftus, investigators at Mayo Clinic and experts in Glioblastoma Multiforme (GBM), collaborated with Oleolive on the proposal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Propentofylline (PPF) was originally tested in multiple clinical trials for Alzheimer’s disease but, although shown to be safe and effective, was not brought to the commercial market. PPF is considered a repurposed drug, defined as a drug developed for one indication and repositioned to treat another, in this case GBM. Repurposed drugs require less money and time for development and overall costs much less compared to research and development of new drugs.

GBM is a brain cancer with no effective therapeutics that claims the lives of over 15,000 Americans each year. GBM has poor clinical outcomes due to therapy-resistant tumor cells leading to recurrence; therefore, therapeutic strategies that enhance tumor cell chemosensitivity are essential for improved patient outcomes. This project will evaluate if PPF increases sensitization of GBM tumor cells to chemotherapy. This research could lead to a therapeutic strategy to extend survival for GBM patients beyond the current average of 1.25 years.

On September 8, 2022 The MedTech company NeoDynamics reported that received approval for its innovative pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA (Press release, NeoDynamics, SEP 8, 2022, View Source [SID1234619295]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The US breast biopsy market is estimated to reach $830 million by 2025.

"The FDA approval for NeoNavia is a major milestone for NeoDynamics and a stamp of quality for both the product and NeoDynamics as a whole," said Anna Eriksrud, CEO of NeoDynamics. "The US represents the potentially largest market for the product, where we now also can build on the experience gained with the system in Europe. Preparation for the launch is ongoing and we expect to begin introducing the system to clinicians and potential partners within the next few months."

NeoDynamics intends to work with US clinics to further document the product in clinical practice to support its marketing and sales strategy. A similar strategy is successfully being executed on in Europe, demonstrating the benefits of the product while forging relationships with important clinics to facilitate a broad acceptance and uptake of the system.

NeoNavia is an innovative biopsy system that uses a patented pulse technology for controlled and accurate needle insertion, which is based on research at Karolinska Institutet. NeoDynamics’ goal is for the pulse technology to become the new standard for ultrasound-guided breast biopsies. The product has CE approval in Europe, where it is in clinical use.